With help from Novartis and Sanofi, NeuroVia heads to the clinic armed with a $14M round
With help from Novartis and Sanofi, NeuroVia heads to the clinic armed with a $14M round
Endpoints
Novartis
Sanofi
NeuroVia
X-ALD
Flag link:
For Biogen's Spinraza launch, things are looking up on the coverage front: analyst
For Biogen's Spinraza launch, things are looking up on the coverage front: analyst
Fierce Pharma
Biogen
Spinraza
drug launches
spinal muscular atrophy
SMA
Flag link:
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
Investors Business Daily
AbbVie
Gilead Sciences
hepatitis C
Vosevi
Harvoni
Sovaldi
Epclusa
Viekira Pak
Flag link:
Here's Why AVEO Oncology Rose as Much as 15% Today
Here's Why AVEO Oncology Rose as Much as 15% Today
Motley Fool
Aveo Oncology
tivozanib
Flag link:
Johnson & Johnson CEO Gorsky: Verb Surgical robotics program ‘on track’
Johnson & Johnson CEO Gorsky: Verb Surgical robotics program ‘on track’
Mass Device
JNJ
Pharma CEOs
Alex Gorsky
Verb Surgical
surgical robots
devices
Flag link:
Pharma's U.S. reputation is bad—and Trump may be to blame: survey
Pharma's U.S. reputation is bad—and Trump may be to blame: survey
Fierce Pharma
Donald Trump
pharma industry
reputation
Flag link:
J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances
J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances
Fierce Pharma
JNJ
Invokana
Eli Lilly
Boehringer Ingelheim
Jardiance
diabetes
Flag link:
July 19 2017 - Novartis CEO Jimenez discusses M&A
Flag link:
Biotech M&A? Novartis chief Jimenez says he’s sticking to the under-$1B aisle for now
Biotech M&A? Novartis chief Jimenez says he’s sticking to the under-$1B aisle for now
Endpoints
Novartis
M&A
Pharma CEOs
Joe Jimenez
Flag link:
Employee alleges Teva hid antitrust, bribery probes
Employee alleges Teva hid antitrust, bribery probes
Drug Delivery Business News
Teva Pharmaceuticals
antitrust
bribery
Flag link:
The flu vaccines are coming: GSK, Sanofi ship the first of more than 150M doses headed to U.S.
The flu vaccines are coming: GSK, Sanofi ship the first of more than 150M doses headed to U.S.
Fierce Pharma
GSK
Sanofi
vaccines
flu vaccines
Seqirus
Flag link:
Does Puma Biotechnology's Approval Make It Worth More?
Does Puma Biotechnology's Approval Make It Worth More?
Motley Fool
Puma Biotechnology
Nerlynx
breast cancer
Flag link:
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
Forbes
drug pricing
hepatitis C
Martin Shkreli
Gilead Sciences
Harvoni
Sovaldi
Flag link:
FDA’s Hatch-Waxman Public Meeting and Progression of the Agency's Drug Competition Action Plan
FDA’s Hatch-Waxman Public Meeting and Progression of the Agency's Drug Competition Action Plan
FDA Law Blog
FDA
Hatch Waxman Act
Scott Gottlieb
Flag link:
Poor test results for Roche cloud growth prospects
Poor test results for Roche cloud growth prospects
Yahoo/Reuters
Roche
biosimilars
Rituxan
Herceptin
Avastin
Flag link:
CAR-T Cell Therapy Is Here To Stay
CAR-T Cell Therapy Is Here To Stay
Forbes
CAR-T
cell therapy
Novartis
Flag link:
GSK puts old antibiotics and UK Horlicks business on the block
GSK puts old antibiotics and UK Horlicks business on the block
Yahoo/Reuters
GSK
antibiotics
MaxiNutrition
M&A
Flag link:
Puma granted broad label for neratinib after FDA OK
Puma granted broad label for neratinib after FDA OK
BioPharma Dive
Puma Biotechnology
neratinib
breast cancer
Nerlynx
Flag link:
5 Ways Gilead Sciences Could Spend Its Cash Hoard
5 Ways Gilead Sciences Could Spend Its Cash Hoard
Motley Fool
Gilead Sciences
dividends
share repurchase
M&A
debt
Flag link:
Eli Lilly buys itself an antibody R&D platform from Tillman Gerngross’s Adimab
Eli Lilly buys itself an antibody R&D platform from Tillman Gerngross’s Adimab
Endpoints
Eli Lilly
R&D
antibodies
Adimab
Flag link: